(IPN) Ipsen - Overview
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic | Exchange PA (France) | Currency EUR | Market Cap: 14.139m | Total Return 46.8% in 12m
Stock: Oncology, Rare Disease, Neuroscience, Biopharma
| Risk 5d forecast | |
|---|---|
| Volatility | 24.6% |
| Relative Tail Risk | -5.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.32 |
| Alpha | 38.79 |
| Character TTM | |
|---|---|
| Beta | 0.275 |
| Beta Downside | 0.301 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.25% |
| CAGR/Max DD | 0.49 |
Description: IPN Ipsen February 25, 2026
Ipsen S.A. (ticker IPN, Paris) is a French biopharmaceutical firm focused on oncology, rare diseases, and neuroscience, developing and commercializing products such as Somatuline, Cabometyx, and Dysport across global markets.
In oncology, Ipsen’s flagship Cabometyx generated €560 million in 2025 sales, while its EZH2 inhibitor Tazverik met its primary endpoint in a Phase III trial for relapsed follicular lymphoma, positioning the company for a potential U.S. launch later this year. Tovorafenib, targeting pediatric low-grade gliomas, received a positive opinion from the EMA in Q4 2025, paving the way for market entry in 2026.
For rare diseases, Bylvay received FDA approval in early 2024 and achieved €120 million in first-year revenue, and Iqirvo was added to the European market in 2025, contributing to a 14% YoY growth in the rare-disease portfolio. In neuroscience, Dysport’s Phase III migraine study showed a statistically significant reduction in migraine days, supporting an expanded label application.
Financially, Ipsen reported 2025 revenue of €4.6 billion, with oncology accounting for 55% of sales and R&D expenses representing 15% of revenue. The European biopharma sector is benefitting from a 7% CAGR in specialty drug spending, a trend that underpins Ipsen’s pipeline-driven growth outlook.
For a deeper quantitative view, you may want to explore Ipsen’s metrics on ValueRay.
Headlines to watch out for
- Cancer drug sales growth drives revenue
- Neuroscience pipeline advancements boost future outlook
- Generic competition erodes mature product sales
- R&D expenses impact profitability
- Exchange rate fluctuations affect international earnings
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 789.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.26 > 0.02 and ΔFCF/TA 3.37 > 1.0 |
| NWC/Revenue: 19.09% < 20% (prev 10.59%; Δ 8.51% < -1%) |
| CFO/TA 0.30 > 3% & CFO 2.05b > Net Income 789.4m |
| Net Debt (-471.4m) to EBITDA (2.29b): -0.21 < 3 |
| Current Ratio: 1.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (82.2m) vs 12m ago -0.61% < -2% |
| Gross Margin: 76.55% > 18% (prev 0.82%; Δ 7.57k% > 0.5%) |
| Asset Turnover: 108.4% > 50% (prev 75.67%; Δ 32.73% > 0%) |
| Interest Coverage Ratio: 26.79 > 6 (EBITDA TTM 2.29b / Interest Expense TTM 59.2m) |
Altman Z'' 5.05
| A: 0.20 (Total Current Assets 2.82b - Total Current Liabilities 1.44b) / Total Assets 6.94b |
| B: 0.06 (Retained Earnings 443.5m / Total Assets 6.94b) |
| C: 0.24 (EBIT TTM 1.59b / Avg Total Assets 6.69b) |
| D: 1.85 (Book Value of Equity 4.82b / Total Liabilities 2.60b) |
| Altman-Z'' Score: 5.05 = AAA |
Beneish M -2.97
| DSRI: 0.90 (Receivables 932.1m/697.2m, Revenue 7.25b/4.87b) |
| GMI: 1.08 (GM 76.55% / 82.42%) |
| AQI: 0.85 (AQ_t 0.50 / AQ_t-1 0.58) |
| SGI: 1.49 (Revenue 7.25b / 4.87b) |
| TATA: -0.18 (NI 789.4m - CFO 2.05b) / TA 6.94b) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of IPN shares?
Over the past week, the price has changed by +0.39%, over one month by -4.80%, over three months by +28.84% and over the past year by +46.79%.
Is IPN a buy, sell or hold?
What are the forecasts/targets for the IPN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 151 | -1.2% |
| Analysts Target Price | - | - |
IPN Fundamental Data Overview March 24, 2026
P/E Trailing = 27.8424
P/E Forward = 15.873
P/S = 3.1124
P/B = 2.8432
P/EG = 0.8254
Revenue TTM = 7.25b EUR
EBIT TTM = 1.59b EUR
EBITDA TTM = 2.29b EUR
Long Term Debt = 834.2m EUR (from longTermDebt, last quarter)
Short Term Debt = 136.3m EUR (from shortTermDebt, last quarter)
Debt = 1.05b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -471.4m EUR (from netDebt column, last quarter)
Enterprise Value = 11.76b EUR (12.23b + Debt 1.05b - CCE 1.53b)
Interest Coverage Ratio = 26.79 (Ebit TTM 1.59b / Interest Expense TTM 59.2m)
EV/FCF = 6.62x (Enterprise Value 11.76b / FCF TTM 1.78b)
FCF Yield = 15.10% (FCF TTM 1.78b / Enterprise Value 11.76b)
FCF Margin = 24.49% (FCF TTM 1.78b / Revenue TTM 7.25b)
Net Margin = 10.89% (Net Income TTM 789.4m / Revenue TTM 7.25b)
Gross Margin = 76.55% ((Revenue TTM 7.25b - Cost of Revenue TTM 1.70b) / Revenue TTM)
Gross Margin QoQ = 59.26% (prev 82.14%)
Tobins Q-Ratio = 1.69 (Enterprise Value 11.76b / Total Assets 6.94b)
Interest Expense / Debt = 1.94% (Interest Expense 20.4m / Debt 1.05b)
Taxrate = 28.79% (44.1m / 153.2m)
NOPAT = 1.13b (EBIT 1.59b * (1 - 28.79%))
Current Ratio = 1.96 (Total Current Assets 2.82b / Total Current Liabilities 1.44b)
Debt / Equity = 0.24 (Debt 1.05b / totalStockholderEquity, last quarter 4.34b)
Debt / EBITDA = -0.21 (Net Debt -471.4m / EBITDA 2.29b)
Debt / FCF = -0.27 (Net Debt -471.4m / FCF TTM 1.78b)
Total Stockholder Equity = 4.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.80% (Net Income 789.4m / Total Assets 6.94b)
RoE = 18.80% (Net Income TTM 789.4m / Total Stockholder Equity 4.20b)
RoCE = 31.51% (EBIT 1.59b / Capital Employed (Equity 4.20b + L.T.Debt 834.2m))
RoIC = 23.31% (NOPAT 1.13b / Invested Capital 4.84b)
WACC = 6.51% (E(12.23b)/V(13.28b) * Re(6.95%) + D(1.05b)/V(13.28b) * Rd(1.94%) * (1-Tc(0.29)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -0.79%
[DCF] Terminal Value 85.54% ; FCFF base≈1.64b ; Y1≈1.85b ; Y5≈2.51b
[DCF] Fair Price = 767.9 (EV 62.81b - Net Debt -471.4m = Equity 63.28b / Shares 82.4m; r=6.51% [WACC]; 5y FCF grow 15.13% → 3.0% )
EPS Correlation: 2.52 | EPS CAGR: 41.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 90.98 | Revenue CAGR: 12.83% | SUE: -0.12 | # QB: 0
EPS current Year (2026-12-31): EPS=12.93 | Chg7d=+0.153 | Chg30d=-0.296 | Revisions Net=+1 | Growth EPS=+7.0% | Growth Revenue=+5.6%
EPS next Year (2027-12-31): EPS=13.04 | Chg7d=+0.255 | Chg30d=+0.364 | Revisions Net=+5 | Growth EPS=+0.8% | Growth Revenue=+4.0%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = -0.3% (Analyst 4.0% - Implied 4.3%)